| 摘要 |
The present invention relates to the use of known and novel compounds as inhibitors of UDP-GlcNAc:Galbeta1,3GaINAc-R (GlcNAc to GalNAc) beta1,6-N-acetylglucosaminyl transferase (core 2 beta1,6 N-acetylaminotransferase, core 2 GlcNAc-T-EC 2.4.1.102). Such inhibitors have applications in therapy for diseases associates with raised activity of core 2 GlcNAc-T, in particular inflammatory diseases, atherosclerosis, diabetic cardiomyopathy, cancers-including treatment or prevention of metastasis-or diabetic retinopathy.
|
